Anne S. Tsao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anne S. Tsao has a total of 823 co-authors. Here are the top co-authors by number of shared publications:
- Gregory J. Riely
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
36 shared publications - Bruce E. Johnson
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
34 shared publications - Keith Wilner
Pfizer Inc, San Diego, CA
34 shared publications - Nada Rifi
Oncology Lung Cancer, Pfizer, Paris, France
33 shared publications - Brian Tunquist
Pfizer, Inc., United States
32 shared publications - Chenming Cui32 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 2 (2) , 13
Faculty Growth Through Academic Career Development Committees
Academic medical centers face ongoing challenges in providing structured, career -stage-–specific faculty development, mentorship, and leadership opportunities that effectively engage faculty throughout their academic careers. The Academic Career Development Committees at The University of Texas MD Anderson Cancer Center represent a structured, faculty-driven model designed to promote professional growth, mentorship, and leadership engagement across all career stages. Grounded in established principles of faculty development and mentorship in academic medicine, the Academic Career Development Committees foster cross-level collaboration, inclusive participation, and intentional skill-building. Outcomes were measured through participant evaluations, attendance and participation trends, mentorship engagement indicators, and qualitative feedback gathered from participant comments and committee discussions. These data demonstrated improved faculty engagement, expanded mentorship opportunities, increased satisfaction, increased clarity in career planning, enhanced interdisciplinary collaboration, and informed continuous program improvement efforts. This initiative offers a scalable and replicable model for strengthening faculty engagement and leadership capacity in academic health systems.
- 27 October 2026
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 2 (2) , 13
Open AccessFaculty Growth Through Academic Career Development Committees
Academic medical centers face ongoing challenges in providing structured, career -stage-–specific faculty development, mentorship, and leadership opportunities that effectively engage faculty throughout their academic careers. The Academic Career Development Committees at The University of Texas MD Anderson Cancer Center represent a structured, faculty-driven model designed to promote professional growth, mentorship, and leadership engagement across all career stages. Grounded in established principles of faculty development and mentorship in academic medicine, the Academic Career Development Committees foster cross-level collaboration, inclusive participation, and intentional skill-building. Outcomes were measured through participant evaluations, attendance and participation trends, mentorship engagement indicators, and qualitative feedback gathered from participant comments and committee discussions. These data demonstrated improved faculty engagement, expanded mentorship opportunities, increased satisfaction, increased clarity in career planning, enhanced interdisciplinary collaboration, and informed continuous program improvement efforts. This initiative offers a scalable and replicable model for strengthening faculty engagement and leadership capacity in academic health systems.
- 20 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (27) , 2651-2652
Reply to: “Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743” and “Beyond Statistical Significance: Methodologic Fragility and Censoring Bias in the 5-Year Update of CheckMate 743”
- 20 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (27) , 2651-2652
Reply to: “Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743” and “Beyond Statistical Significance: Methodologic Fragility and Censoring Bias in the 5-Year Update of CheckMate 743”
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
PHAROS study design and participants, clinical validation, and F1CDx analyses
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
PHAROS study design and participants, clinical validation, and F1CDx analyses
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S6. Summary statistics of F1LCDx test PPA and PPV after including imputed data
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S6. Summary statistics of F1LCDx test PPA and PPV after including imputed data
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
PHAROS study design and participants, clinical validation, and F1CDx analyses
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
PHAROS study design and participants, clinical validation, and F1CDx analyses
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S7. Summary statistics of ORR for the F1LCDx+/CTA+ population (ƍ1) on imputed complete data
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S7. Summary statistics of ORR for the F1LCDx+/CTA+ population (ƍ1) on imputed complete data
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S4. Contingency table comparing BRAF V600E status between the CTA and F1CDx
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S4. Contingency table comparing BRAF V600E status between the CTA and F1CDx
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S7. Summary statistics of ORR for the F1LCDx+/CTA+ population (ƍ1) on imputed complete data
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S7. Summary statistics of ORR for the F1LCDx+/CTA+ population (ƍ1) on imputed complete data
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S3. Concordance analysis results between CTA and F1LCDx tests
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S3. Concordance analysis results between CTA and F1LCDx tests
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S1. Demographics and clinical characteristics in the F1CDx-evaluable and -unevaluable populations
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S1. Demographics and clinical characteristics in the F1CDx-evaluable and -unevaluable populations